Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 221 to 230 of 653 total matches.

A Morphine/Naltrexone Combination (Embeda) for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010  (Issue 1334)
mg caps 3 Morphine – extended-release generic 15, 30, 60, 100, 200 mg tabs 15-30 mg 8 hrs 2.67 ...
The FDA has approved an agonist/antagonist combination of morphine and naltrexone (Embeda – King) for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Med Lett Drugs Ther. 2010 Mar 22;52(1334):22-3 |  Show IntroductionHide Introduction

Clarithromycin in Patients with Coronary Artery Disease

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
Sinusitis2 Amoxicillin/clavulanate 875/125 mg Cefpodoxime 200 mg PO bid x 5-7 days4 (Streptococcus ...
The FDA has warned that use of the macrolide antibiotic clarithromycin (Biaxin, and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
Med Lett Drugs Ther. 2018 May 21;60(1547):89-90 |  Show IntroductionHide Introduction

Solriamfetol (Sunosi) for Excessive Daytime Sleepiness

   
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019  (Issue 1579)
Drug Schedule Formulations Maintenance Dosage Cost1 Armodafinil – generic C-IV 50, 150, 200, 250 mg ...
The FDA has approved solriamfetol (Sunosi – Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Pitolisant (Wakix), an H3-receptor antagonist/inverse agonist recently approved by the FDA for treatment of excessive daytime sleepiness in patients with narcolepsy, will be reviewed in a future issue.
Med Lett Drugs Ther. 2019 Aug 26;61(1579):132-4 |  Show IntroductionHide Introduction

Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
either ER cabotegravir 600 mg intramuscularly once every 2 months or FTC/TDF 200/300 mg orally once ...
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents and adults. Apretude is the first ER formulation to be FDA-approved for pre-exposure prophylaxis (PrEP) of HIV-1 infection.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):29-31 |  Show IntroductionHide Introduction

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
daily 188.39 H 2 -Receptor Antagonists 6-8,12 Cimetidine – generic 200, 300, 400, 800 mg tabs 200 ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Med Lett Drugs Ther. 2010 Mar 8;52(1333):17-9 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Gout (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
-Inflammatory Drugs Celecoxib – generic Celebrex (Viatris) 50, 100, 200, 400 mg caps Acute flare: 400 mg PO ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9   doi:10.58347/tml.2023.1688c |  Show IntroductionHide Introduction

In Brief: Expanded Access to Mifepristone

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose ...
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31   doi:10.58347/tml.2023.1670c |  Show IntroductionHide Introduction

Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
vials 500 mg/5 mL, 200 mg/2mL single-dose vials Dosage 700 mg x 3 doses, then 1400 mg 10 mg/kg ...
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2   doi:10.58347/tml.2024.1708e |  Show IntroductionHide Introduction

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
400 mg PO once/day x 5-7 days6 Cefpodoxime 200 mg PO bid x 5-7 days6 Penicillin Allergy (severe ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a |  Show IntroductionHide Introduction

Sinemet CR For Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991  (Issue 854)
— Sinemet CR is supplied as sustained-release tablets containing 50 mg of carbidopa and 200 mg of levodopa ...
Controlled-release carbidopa/levodopa (Sinemet CR - Dupont Pharma) was recently approved by the US Food and Drug Administration for treatment of Parkinson's disease. The new formulation of this old combination (Sinemet) has the drugs suspended in a polymeric matrix that erodes slowly in the gastrointestinal tract.
Med Lett Drugs Ther. 1991 Oct 4;33(854):92-3 |  Show IntroductionHide Introduction